Omeros Corporation reported earnings results for the fourth quarter and full year ended December 31, 2024. For the fourth quarter, the company reported net loss was USD 31.36 million compared to USD 9.07 million a year ago. Basic loss per share from continuing operations was USD 0.63 compared to USD 0.63 a year ago. Diluted loss per share from continuing operations was USD 0.63 compared to USD 0.63 a year ago. Basic loss per share was USD 0.54 compared to USD 0.15 a year ago. Diluted loss per share was USD 0.54 compared to USD 0.15 a year ago. For the full year, net loss was USD 156.82 million compared to USD 117.81 million a year ago. Basic loss per share from continuing operations was USD 3.14 compared to USD 2.79 a year ago. Diluted loss per share from continuing operations was USD 3.14 compared to USD 2.79 a year ago. Basic loss per share was USD 2.7 compared to USD 1.88 a year ago. Diluted loss per share was USD 2.7 compared to USD 1.88 a year ago.
Omeros is a Wasington-based biopharmaceutical company that researches and develops small-molecule and protein therapeutics for the treatment of inflammation and CNS disorders.